Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person

Current HIV/AIDS Reports

Volumn 12, Issue 3, 2015, Pages 336-343

  El Sherif, O ^a   Back, D ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Direct acting antivirals; Drug interactions; Hepatitis C; HIV HCV co infection; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DACLATASVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELBASVIR; ELBASVIR PLUS GRAZOPREVIR; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; LOPINAVIR PLUS RITONAVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SAFETY; EVENING DOSAGE; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MORNING DOSAGE; NAUSEA; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VOMITING; CLINICAL TRIAL (TOPIC); COINFECTION; COMPLICATION; DRUG INTERACTION; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 84938834763     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-015-0277-5     Document Type: Review

References (45)

1. Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
2. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57(4):743–51.
3. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;365:1445–54.
4. Amin J, Kaye M, Skidmore S, et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004;5:174–9.
5. Chen J, Feeney E, Chung R. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:363–71.
6. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; doi:10.1016/j.jhep.2015.03.025These recent recommendations provide guidance on treating patients with HIV/HCV co-infection, including a detailed section on clinical pharmacology and drug-drug interactions.
7. American Association of the study of liver diseases (AASLD)-Infectious Diseases Society of America (IDSA) recommendations for testing, managing, and treating Hepatitis C. http://www.hcvguidelines.org. Clinical guidance in the USA for the use of HCV direct-acting antiviral as well as guidance on drug-drug interactions and their management in this with HIV/HCV co-infection.
8. Van Der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.
9. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complication and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13.
10. Laguno M, Cifuentes C, Murillas J, et al. Randomised trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49(1):22–31.
11. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomised trial. Ann Intern Med. 2013;159:86–96.
12. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597–605.
13. Karageorgopoulos D, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coninfection. Curr Opin Infect Dis. 2014;27:36–45.
14. Hodgson K. ADMET—turning chemicals into drugs. Nat Biotechnol. 2001;19(8):722–6.
15. The International Transporter consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.
16. Kiser J, Burton JR, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
17. German P, Pang PS, West S et al. Drug interactions between direct-acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. Abstract: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2014; Washington, DC.
18. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med. 2015, in press. This large phase III study demonstrated the safety and efficacy of this DAA combination in the setting of HIV/HCV co-infection and provides valuable safety data and interaction data for several antiretroviral combinations when given with sofosbuvir and ledipasvir.
19. Kirby B, Mathias A, Rossi S et al. No clinically significant interactions between GS-7977 and HIV antiretrovirals Atripla, rilpivirine, darunavir or raltegravir in healthy volunteers. Abstract No 1877: 63rd Annual Meeting of the American Association for the Study of Liver Disease; 2012; Boston, MA.
20. German P, Garrison K, Pang PS et al. Drug interactions between the anti-HCV regimen ledipasvir/sofosbuvir and ritonavir boosted protease inhibitors plus FTC/TDF. Abstract: 22nd Conference on Retroviruses and Opportunistic Infections; 2015; Seattle, Washington.
21. Garrison K, Custodio J, Pang P et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens. Abstract: 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2015; Washington, DC.
22. Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. J Hepatol. 2010;52(S1):S416.
23. Ouwerkerk-Mahadevan S, Sekar V, Simion A et al. The pharmacokinetic interactions of the HCV protease inhibitor TMC-435 with HIV antiretroviral agents in healthy volunteers. Abstract: Infectious Disease Society Association Conference; 2012; San Diego, CA.
24. Eley T, You X, Wang R, et al. Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs. Abstract: HIV DART; 2014; Miami, FL.
25. Bristol-Myers Squibb. Daklinza film-coated tablets. [Prescribing Information]. BMS Pharmaceutical Ltd, Middlesex, United Kingdom.
26. Bow DAJ, Liu J, Kavetskaia O et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the HCV regimen: ABT-450/r, ombitasvir, and dasabuvir. Poster Presentation: AASLD/EASL Special Conference on Hepatitis C, 2014.
27. Menon R, Badri P, Khatri A et al. ABT-450/ritonavir + ombitasvir + dasabuvir: drug interactions mediated by transporters. Abstract: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 2014.
28. AbbVie Corporation. Viekerax 12.5mg/75mg/50mg film-coated tablet. [Prescribing Information] AbbVie Ltd, Maidenhead, United Kingdom.
29. AbbVie Corporation. Exviera 250mg film-coated tablet. [Prescribing Information] AbbVie Ltd, Maidenhead, United Kingdom.
30. Menon R, Badri P, Wang T, et al. Drug-drug interaction profile of the All-oral hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol. 2015;63:20–9.
31. Khatri A, Wang T, Wang H et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with HIV protease inhibitors. Abstract: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2014; Washington DC.
32. Kharti A, Wang T, Wang H et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz. Abstract: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2014; Washington DC.
33. Yeh W, Marenco T, Feng H-P et al. Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir. Abstract: 22nd Conference on Retroviruses and Opportunistic Infections; 2015; Seattle, Washington.
34. Yeh W, Fraser IP, Caro L et al. No meaningful PK interaction between the HCV protease inhibitor MK-5172 and tenofovir or raltegravir. Abstract: Conference on retroviruses and opportunistic infections (CROI), 2014, Boston, MA.
35. Caro L, Talaty JE, Guo Z et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir boosted protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers. Abstract 487: 64th Annual Meeting of the American Association for the Study of Liver diseases (AASLD), 2013, Washington DC.
36. Yeh WY, Marshall W, Ma J et al. Ritonavir-boosted atazanavir, lopinavir, and darunavir increase HCV NS5A inhibitor MK-8742 levels. Abstract: Conference on retroviruses and opportunistic infections (CROI), 2014, Boston, MA.
37. Talaty JE, Carol L, Yeh W et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers. Abstract 492: 64th Annual Meeting of the American Association for the Study of Liver diseases (AASLD), 2013, Washington DC.
38. Yeh W, Marshall W, Mangin E et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz. Abstract: Conference on retroviruses and opportunistic infections (CROI), 2014, Boston, MA.
39. Wyles DL, Ruane P, Sulkowski MS et al. Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV co-infection: the ALLY-2 study. Abstract: 50th annual meeting of the European association for the study of the liver, April 22–26, Vienna, Austria.
40. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomised trial. JAMA. 2015;313(12):1223–31. A phase IIb study which provides a proof of concept of the efficacy of this augmented triple therapy regimen in patients with HIV-HCV co-infection as well as safety data of this combination with NNRTI-based regimens with atazanavir and raltegravir.
41. Rockstroch J, Nelson M, Katlama C et al. C-Edge coinfection: phase 3 study of grazoprevir and elbasvir in patients with HCV/HIV. Abstract: 50th annual meeting of the European association for the study of the liver, April 22–26, Vienna, Austria. High SVR rates were observed with the combination of grazoprevir and elbasvir in this phase III study of treatment naïve cirrhotics and non-cirrhotics with HIV infection and HCV genotypes 1 and 4.
42. Herold C, Heinz R, Niedobitek G, et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver. 2001;21:260–5.
43. Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology. 2001;34:1103–8.
44. German P, Yang J, West S et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed-dose combination tablet. Abstract: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 2014.
45. FDA. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another direct acting antiviral drug. Available at http://www.fda.gov. Accessed 15 June 2015.